Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ABL1 |
Variant | M351T |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | ABL1 M351T lies within the protein kinase domain of the Abl1 protein (UniProt.org). M351T results in loss of inhibitor binding (PMID: 24456693) and decreased kinase activity in cell culture (PMID: 33820471), has been demonstrated to occur as a secondary resistance mutation (PMID: 16046538, PMID: 16880519), and in the context of BCR-ABL1 leads to decreased transformation activity and kinase activity compared to wild-type BCR-ABL1 (PMID: 16046538, PMID: 16880519), and therefore, is predicted to lead to a loss of Abl1 protein function. |
Associated Drug Resistance | Y |
Category Variants Paths |
ABL1 mutant ABL1 inact mut ABL1 M351T |
Transcript | NM_005157.6 |
gDNA | chr9:g.130873004T>C |
cDNA | c.1052T>C |
Protein | p.M351T |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |